Extracellular vesicles as liquid biopsy tools for personalized therapeutic goals in glioblastoma
(2026) In Brain 149(5). p.1452-1468- Abstract
Although there has been a considerable increase in the understanding of glioblastoma and investigations into the therapeutic utility of several novel putative active compounds, the prognosis of glioblastoma patients remains dismal. This paradox makes glioblastoma a unique disease, in which the availability of key molecular and biological insight does not translate into therapeutic discovery or improved outcomes. Much of the challenge in glioblastoma treatment is attributable to a dearth of tools capable of accurately selecting patients who might benefit from current standard-of-care or targeted therapies. Moreover, the lack of reliable circulating biomarkers also delays treatment initiation and hampers evaluation of the therapeutic... (More)
Although there has been a considerable increase in the understanding of glioblastoma and investigations into the therapeutic utility of several novel putative active compounds, the prognosis of glioblastoma patients remains dismal. This paradox makes glioblastoma a unique disease, in which the availability of key molecular and biological insight does not translate into therapeutic discovery or improved outcomes. Much of the challenge in glioblastoma treatment is attributable to a dearth of tools capable of accurately selecting patients who might benefit from current standard-of-care or targeted therapies. Moreover, the lack of reliable circulating biomarkers also delays treatment initiation and hampers evaluation of the therapeutic response. However, the emergence of a personalized medicine paradigm using extracellular vesicles has the potential to revolutionize cancer treatment, bringing renewed hope for patients with glioblastoma. In this review, we provide a brief overview of the current standard-of-care therapies, immunotherapeutic approaches and their clinical limitations. We then introduce the need for a personalized model and discuss the conceptual underpinnings of how extracellular vesicle cargo as a superior liquid biopsy tool can be used for a new personalized therapeutic approach in glioblastoma.
(Less)
- author
- Menaceur Vandenbroucke, Camille ; Unnikrishnan, Kavitha ; Ita, Michael Itak ; Lassen, Ulrik Niels ; Belting, Mattias LU ; Korshoej, Anders Rosendal ; Bjarkam, Carsten Reidies and Indira Chandran, Vineesh
- organization
- publishing date
- 2026-05
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- circulating biomarkers, extracellular vesicles, glioblastoma, liquid biopsy, personalized medicine
- in
- Brain
- volume
- 149
- issue
- 5
- pages
- 17 pages
- publisher
- Oxford University Press
- external identifiers
-
- pmid:41492781
- scopus:105037811504
- ISSN
- 0006-8950
- DOI
- 10.1093/brain/awag003
- language
- English
- LU publication?
- yes
- id
- cda80859-5830-4d67-9798-bd202c177dcb
- date added to LUP
- 2026-07-07 11:31:25
- date last changed
- 2026-07-07 11:31:49
@article{cda80859-5830-4d67-9798-bd202c177dcb,
abstract = {{<p>Although there has been a considerable increase in the understanding of glioblastoma and investigations into the therapeutic utility of several novel putative active compounds, the prognosis of glioblastoma patients remains dismal. This paradox makes glioblastoma a unique disease, in which the availability of key molecular and biological insight does not translate into therapeutic discovery or improved outcomes. Much of the challenge in glioblastoma treatment is attributable to a dearth of tools capable of accurately selecting patients who might benefit from current standard-of-care or targeted therapies. Moreover, the lack of reliable circulating biomarkers also delays treatment initiation and hampers evaluation of the therapeutic response. However, the emergence of a personalized medicine paradigm using extracellular vesicles has the potential to revolutionize cancer treatment, bringing renewed hope for patients with glioblastoma. In this review, we provide a brief overview of the current standard-of-care therapies, immunotherapeutic approaches and their clinical limitations. We then introduce the need for a personalized model and discuss the conceptual underpinnings of how extracellular vesicle cargo as a superior liquid biopsy tool can be used for a new personalized therapeutic approach in glioblastoma.</p>}},
author = {{Menaceur Vandenbroucke, Camille and Unnikrishnan, Kavitha and Ita, Michael Itak and Lassen, Ulrik Niels and Belting, Mattias and Korshoej, Anders Rosendal and Bjarkam, Carsten Reidies and Indira Chandran, Vineesh}},
issn = {{0006-8950}},
keywords = {{circulating biomarkers; extracellular vesicles; glioblastoma; liquid biopsy; personalized medicine}},
language = {{eng}},
number = {{5}},
pages = {{1452--1468}},
publisher = {{Oxford University Press}},
series = {{Brain}},
title = {{Extracellular vesicles as liquid biopsy tools for personalized therapeutic goals in glioblastoma}},
url = {{http://dx.doi.org/10.1093/brain/awag003}},
doi = {{10.1093/brain/awag003}},
volume = {{149}},
year = {{2026}},
}